Cellares and TScan Agree to Evaluate Automated Manufacturing TSC-101 for Patients with Hematologic Malignancies

Cellares, TScan to assess automated manufacturing of TSC-101 therapy

The collaboration aims to conduct a full technical and operational assessment of Cellares’ automated manufacturing and testing platforms. This is in preparation for the anticipated demand surrounding TSC-101 The post Cellares and TScan to assess automated manufacturing of TSC-101 therapy appeared first on Pharmaceutical Business review.

Cellares and TScan Agree to Evaluate Automated Manufacturing TSC-101 for Patients with Hematologic Malignancies

IDMO Cellares and TScan Therapeutics will work together to evaluate automated clinical manufacturing of TSC-101, which is TScan’s lead TCR-T therapy candidate for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). TSC-101 is designed to treat residual disease and prevent relapse in patients with AML and MDS undergoing allogeneic hematopoietic cell transplantation (allo-HCT). The therapy candidate uses a gene modifica…